Sustained clinical response of large hepatocellular carcinoma after chemoembolization with pirarubicin, amiodarone and lipiodol®;Réponse majeure d'un volumineux carcinome hépatocellulaire à une chimioembolisation par pirarubicine, amiodarone et lipiodol®

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 12, 2004, Pages 1281-1283

  Cercueil, Jean Pierre ^a   Ferrant, Emmanuelle ^b   Isambert, Nicolas ^b   Jouve, Jean Louis ^a   Flesch, Michel ^c   Krause, Denis ^a   Bedenne, Laurent ^a   Chauffert, Bruno ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Ctr Reg de Lutte Contre le Cancer   (France)

^c Fondation Drevon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTHRACYCLINE; DOXORUBICIN; IODINATED POPPYSEED OIL; PIRARUBICIN; POLYSORBATE 80;

ARTICLE; CANCER CELL; CANCER PALLIATIVE THERAPY; CASE REPORT; CHEMOEMBOLIZATION; CLINICAL FEATURE; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; HUMAN; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; TREATMENT OUTCOME;

EID: 11244261407     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(04)95221-9     Document Type: Article

References (12)

1. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
2. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
3. Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharek MS. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol 2003;26:344-9.
4. Favoulet P, Cercueil JP, Faure, Osmak L, Isambert, Beltramo JL, et al. Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs 2001;12:801-6.
5. Suzuki M, Suzuki H, Yamamoto T, Mamada Y, Mizuno H, Tominaga T, et al. Indication of chemoembolization therapy without gelatin sponge for hepatocellular carcinoma. Semin Oncol 1997;24:110-5.
6. Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol 2002;35:138-42.
7. Barone M, Ettorre GC, Ladisa R, Schiavariello M, Santoro C, Francioso G, et al. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology 2003;50:183-7.
8. Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002;20:4459-65.
9. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003;97:1042-50.
10. Tapiero H, Munck JN, Fourcade A. Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo. Drugs Exp Clin Res 1986;12:257-64.
11. Munck JN, Rougier, Chabot GG, Ramirez LH, Bognel C, Lumbroso J, et al. Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases. Eur J Cancer 1994;30:289-94.
12. Chauffert B, Martin M, Hammann A, Michel MF, Martin F. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 1986;46:825-30.